NICE recommends natalizumab for the treatment of multiple sclerosis
The National Institute for Health and Clinical Excellence (NICE) has today issued guidance recommending natalizumab for the treatment of rapidly evolving severe relapsing-remitting multiple sclerosis (RES). This guidance is produced as part of its rapid single technology appraisal (STA) work programme.
NICE recommends natalizumab for the treatment of multiple sclerosis
22 August 2007 (34.01 Kb 9 sec) |
This page was last updated: 30 March 2010